Community-acquired bacterial pneumonia (CABP) is a common respiratory infection caused by various bacterial pathogens that affect individuals who have not recently been hospitalized or had contact with healthcare settings. The CABP treatment drugs market includes a range of antibiotics and other drugs used to treat the condition.
Drivers:
Increasing Prevalence of CABP: The increasing incidence and prevalence of CABP are the primary drivers of the CABP treatment drugs market. The rising number of cases of pneumonia worldwide is expected to drive market growth.
Advancements in Drug Development: Advancements in drug development, including the development of new antibiotics and therapies, are driving the growth of the Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market. The development of new drugs with improved efficacy and safety profiles is expected to increase demand for CABP treatment drugs.
Government Initiatives: The government initiatives to promote research and development of new drugs and therapies are expected to fuel the growth of the CABP treatment drugs market. The increasing focus on healthcare infrastructure development and healthcare access in emerging economies is expected to increase the demand for CABP treatment drugs.
The high incidence of community-acquired pneumonia is anticipated to increase demand for medications that treat CABP, which will fuel market expansion throughout the forecast period. For instance, an article from the Asian Pacific Association of Respirology from 2017 states that in Central Vietnam, the incidence of all-cause CAP was predicted to be 0.81 per 1,000 people each year, increasing to 6.95 per 1,000 people each year among those who were 75 or older.
Moreover, the impact of HIV was a major factor in the rising prevalence of CAP. For instance, according to the Asian Pacific Association of Respirology, a 2017 paper claims that in 2017, HIV was the primary cause of CAP if untreated, which was linked to a 17- to 35-fold rise in pneumococcal pneumonia in the Sub-Saharan Africa area.
Read More:
https://knackersblogger.blogspot.com/2023/03/community-acquired-bacterial-pneumonia.html
Community-acquired pneumonia (CAP) refers to pneumonia that is acquired in the community setting, which is caused by various bacterial species, such as S. pneumoniae, Haemophilus influenzae type b (Hib), Chlamydia pneumoniae, Mycoplasma, pneumoniae, or Legionella spp., and many others.
Prevalence of pneumonia differs both regionally and by age group affecting from children to adults.The global community-acquired bacterial pneumonia (CABP) treatment drugs market is estimated to be valued at US$ 1,269.73 million in 2020 and is expected to exhibit a CAGR of 7.2% during the forecast period (2020-2027).The increasing prevalence of community-acquired pneumonia is expected to propel growth of the global community-acquired bacterial pneumonia (CABP) treatment drugs marketGet PDF Brochure Of This Research Report @https://www.coherentmarketinsights.com/insight/request-sample/4269High prevalence of community-acquired pneumonia is expected to propel demand for community-acquired bacterial pneumonia (CABP) treatment drugs, which is expected to drive the market growth over the forecast period.
For instance, according to the Asian Pacific Society of Respirology, an article published in 2017, reports that the incidence of all?cause CAP each year was estimated at 0.81 per 1,000 individuals , rising to 6.95 per 1,000 person year in those aged 75 or older in Central Vietnam.Moreover, increasing incidence of CAP were dominated by the effect of HIV.
to 35?fold increase in pneumococcal pneumonia in Sub-Saharan Africa region.However, inappropriate treatment due to incorrect identification of pathogen contribute to the limited use of current drugs in the management of CABP.
For instance, according to an article published in November 2019 in the National Center for Biotechnology Information (NCBI), the presence of multiple pathogens in patients leads to incorrect selection of initial antibiotic, which may affect the mortality outcome in CABP.
Such inappropriate medication are expected to hamper the market growth.Increasing incidence of CAP in North America is expected to boost the market growthNorth America is expected to hold dominant position in the global community-acquired bacterial pneumonia (CABP) treatment drugs market, owing to rising incidence of community-acquired pneumonia in the region especially in the U.S. For instance, according to the Asian Pacific Society of Respirology, an article published in 2017, reports that in the U.S. overall incidence of community-acquired pneumonia in adults was around 2.5 per 1000 person, rising to 6.3 and 16.4 per 1000 person in adults aged 65-79 and 80 years or older in 2017.
Global Bacterial Pneumonia Treatment Market: OverviewBacterial pneumonia is an inflammation of the lungs due to bacterial infection.
Different types of bacteria can cause pneumonia, but Streptococcus pneumonia and Haemophilus influenza are primarily responsible for most of the bacterial pneumonia.
Grab an Exclusive PDF Brochure of Bacterial Pneumonia Treatment Market ReportBacterial pneumonia is caused by bacteria that works its way into the lungs and then multiplies.
According to the Cleveland Clinics, people who have a weakened immune system as a result of cancer or organ transplant face an increased risk of bacterial pneumonia.The global bacterial pneumonia treatment market is projected to grow at a significant pace during the forecast period, owing to increase in the rate of incidence of bacterial pneumonia across the globe and continuous R activities for the development of vaccines and new drugs for bacterial pneumonia.Request COVID Analysis on Bacterial Pneumonia Therapeutics Market – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19_id=76655 Key Drivers of Global Bacterial Pneumonia Treatment MarketAntibiotics are becoming ineffective against bacterial pneumonia due to increase in resistance of bacteria.
This is expected to increase the rate of cure of bacterial pneumonia in the near future.Nabriva Therapeutics AG is a biotechnology company involved in the development of pleuromutilins, a new class of antibiotics to treat community-acquired bacterial pneumonia (CABP)The continuing need of reinventing the drug pipeline, led by bacterial mutation and resistance, presents an opportunity in the global bacterial pneumonia treatment marketRequest Customization on Bacterial Pneumonia Therapeutics Market Report –https://www.transparencymarketresearch.com/sample/sample.php?flag=CR_id=76655Restraints of Global Bacterial Pneumonia Treatment MarketPathways to the approval for bacterial pneumonia drugs from regulatory bodies have become confusing, generally infeasible, and questionably irrelevant to patients and providers over a period of time.
According to the World Health Organization (WHO), one in three deaths in India is caused by pneumonia.
